Iterative refinement graph neural network for antibody sequence-structure co-design
arXiv preprint arXiv:2110.04624, 2021•arxiv.org
Antibodies are versatile proteins that bind to pathogens like viruses and stimulate the
adaptive immune system. The specificity of antibody binding is determined by
complementarity-determining regions (CDRs) at the tips of these Y-shaped proteins. In this
paper, we propose a generative model to automatically design the CDRs of antibodies with
enhanced binding specificity or neutralization capabilities. Previous generative approaches
formulate protein design as a structure-conditioned sequence generation task, assuming the …
adaptive immune system. The specificity of antibody binding is determined by
complementarity-determining regions (CDRs) at the tips of these Y-shaped proteins. In this
paper, we propose a generative model to automatically design the CDRs of antibodies with
enhanced binding specificity or neutralization capabilities. Previous generative approaches
formulate protein design as a structure-conditioned sequence generation task, assuming the …
Antibodies are versatile proteins that bind to pathogens like viruses and stimulate the adaptive immune system. The specificity of antibody binding is determined by complementarity-determining regions (CDRs) at the tips of these Y-shaped proteins. In this paper, we propose a generative model to automatically design the CDRs of antibodies with enhanced binding specificity or neutralization capabilities. Previous generative approaches formulate protein design as a structure-conditioned sequence generation task, assuming the desired 3D structure is given a priori. In contrast, we propose to co-design the sequence and 3D structure of CDRs as graphs. Our model unravels a sequence autoregressively while iteratively refining its predicted global structure. The inferred structure in turn guides subsequent residue choices. For efficiency, we model the conditional dependence between residues inside and outside of a CDR in a coarse-grained manner. Our method achieves superior log-likelihood on the test set and outperforms previous baselines in designing antibodies capable of neutralizing the SARS-CoV-2 virus.
arxiv.org